T Cell Lymphoma clinical trials at UC Irvine

• A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)

  open to eligible people ages 18 years and up

  This is a multi-center, parallel cohort, open-label, Phase 2 study of duvelisib, an oral dual inhibitor of PI3K-δ,γ, in patients with relapsed or refractory Peripheral T cell Lymphoma (PTCL).

  Irvine, California and other locations

Last updated: March 15, 2021